KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Other financing activities: 2016-2023

Historic Other financing activities for Ionis Pharmaceuticals (IONS) over the last 5 years, with Sep 2023 value amounting to $517,000.

  • Ionis Pharmaceuticals' Other financing activities fell 19.72% to $517,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $2.3 million, marking a year-over-year decrease of 78.45%. This contributed to the annual value of $14.2 million for FY2023, which is 29.42% up from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Other financing activities of $517,000 as of Q3 2023, which was down 29.76% from $736,000 recorded in Q4 2022.
  • In the past 5 years, Ionis Pharmaceuticals' Other financing activities ranged from a high of $15.3 million in Q1 2021 and a low of $367,000 during Q2 2020.
  • Moreover, its 3-year median value for Other financing activities was $517,000 (2023), whereas its average is $3.1 million.
  • Its Other financing activities has fluctuated over the past 5 years, first skyrocketed by 1,584.48% in 2019, then crashed by 90.84% in 2020.
  • Quarterly analysis of 5 years shows Ionis Pharmaceuticals' Other financing activities stood at $401,000 in 2019, then increased by 12.22% to $450,000 in 2020, then dropped by 2.22% to $440,000 in 2021, then surged by 67.27% to $736,000 in 2022, then dropped by 19.72% to $517,000 in 2023.
  • Its Other financing activities stands at $517,000 for Q3 2023, versus $736,000 for Q4 2022 and $644,000 for Q3 2022.